Company
ShennonBio
Precision Immunotherapies for Solid Tumors Built on Functional Biology at the Single-Cell Level
Also known as Shennon Biotechnologies Inc.
- Status
- Operatingas of 2026-09-18
- Business model
- B2B
- Headquarters
- San Francisco, CA, United States
- Founded
- 2021
- Legal name
- Shennon Biotechnologies Inc.
Claim, correct or request removal
Record updated 28 September 2026
About
We further combine this platform with computational engineering and translational immunology into a unified engine to develop more selective and safer therapeutics, starting with next-generation T-cell engagers against both surface and intracellular cancer targets.
Funding snapshot
- Total raised
- $25MSum of rounds, as of 2026-09-18Source (opens in a new tab)
- Latest round
- Undisclosed, $12M2026-09-14
Funding rounds
- Financing
- $12M2026-09-14, Company stated
- Seed
- $13M2023-03-13, Company stated
- Round, 2022
- $7.3M2022-12-21, SEC form D sold, 9 investors
Loading relationship preview